Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.39 |
| ▸ | GLRB | P48167 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PRKCI | P41743 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NPM1 | P06748 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17673642 | 0.84 | HSD17B10 (0.42) | FABP4DRD2SLC6A4KMT2APRKCI | |
| SCHEMBL15944158 | 0.83 | PRMT5 (0.40) | PRMT5GLRA3GLRBDRD2SLC6A4 | |
| SCHEMBL17678098 | 0.81 | GAA (0.47) | DRD2SLC6A4PRKCIATMHSD17B10 | |
| SCHEMBL31228863 | 0.81 | GAA (0.50) | DRD2SLC6A4HTTMEN1KMT2A | |
| SCHEMBL15943763 | 0.81 | PRMT5 (0.39) | PRMT5GLRA3GLRBDRD2SLC6A4 | |
| SCHEMBL13967316 | 0.81 | HCAR1 (0.50) | FABP4PRMT5DRD2SLC6A4PRKCI | |
| SCHEMBL15824855 | 0.80 | PRKCI (0.51) | FABP4PRMT5DRD2SLC6A4HTT | |
| SCHEMBL17678260 | 0.80 | LRRK2 (0.42) | FABP4PRMT5GLRA3GLRBDRD2 | |
| SCHEMBL31144588 | 0.80 | GAA (0.52) | HTTMEN1KMT2AATMHSD17B10 | |
| SCHEMBL29548797 | 0.80 | LRRK2 (0.42) | FABP4PRMT5GLRA3GLRBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298010-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-10-18 | — | — | US | disclosed |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-07-05 | — | — | US | disclosed |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-07-05 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8906900-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906900-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906900-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014100695-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100695-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298010-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | FABP4 4114/4885PRMT5 1/4885GLRA3 2688/4885 |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | FABP4 4170/4885PRMT5 1/4885GLRA3 2789/4885 |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | FABP4 4170/4885PRMT5 1/4885GLRA3 2789/4885 |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | FABP4 4170/4885PRMT5 1/4885GLRA3 2789/4885 |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | FABP4 4170/4885PRMT5 1/4885GLRA3 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.